Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody

Changhua Ji, Yang Liu, Chandra Pamulapati, Sandhya Bohini, Georg Fertig, Michael Schraeml, Werner Rubas, Michael Brandt, Stefan Ries, Han Ma, Klaus Klumpp – 22 November 2014 – CD81 is a required receptor for hepatitis C virus (HCV) infection of human hepatocytes in vitro. We generated several high‐affinity anti‐human CD81 monoclonal antibodies (mAbs) that demonstrated potent, specific, and cross‐genotype inhibition of HCV entry.

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Adrian M. Bisceglie, Anna S. Lok, Paul Martin, Norah Terrault, Robert P. Perrillo, Jay H. Hoofnagle – 21 November 2014 – Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti‐CD20 agents ofatumumab or rituximab.

Subscribe to